 [
    {
        "id": 5178,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "NCT02563002",
        "has_trial_insight_page": 0,
        "indication": "Colorectal cancer (CRC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-29",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200629005810\/en\/",
        "note": "FDA Approval announced June 29, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5039,
        "drug_name": "Subcutaneous PERJETA (Pertuzumab) and (HERCEPTIN) Trastuzumab",
        "clinical_trial_id": "NCT03493854",
        "has_trial_insight_page": 0,
        "indication": "HER2-positive early breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-29",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/e09ef461-e8d9-440f-a1f3-dae585d9b24f",
        "note": "FDA Approval announced June 29, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5039,
        "drug_name": "Subcutaneous PERJETA (Pertuzumab) and (HERCEPTIN) Trastuzumab",
        "clinical_trial_id": "NCT03493854",
        "has_trial_insight_page": 0,
        "indication": "HER2-positive early breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-29",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/e09ef461-e8d9-440f-a1f3-dae585d9b24f",
        "note": "FDA Approval announced June 29, 2020.",
        "company_entity_id": 156,
        "company_ticker": "HALO",
        "company_name": "Halozyme Therapeutics Inc.",
        "company_price": "41.9500",
        "company_change": 0.75,
        "company_percent_change": 1.8199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 126824800,
        "price_change_sparkline": [
            [
                33.85,
                1706677200
            ],
            [
                34.26,
                1706763600
            ],
            [
                33.68,
                1706850000
            ],
            [
                33.68,
                1707109200
            ],
            [
                35.02,
                1707195600
            ],
            [
                35.31,
                1707282000
            ],
            [
                35.24,
                1707368400
            ],
            [
                35.49,
                1707454800
            ],
            [
                35.69,
                1707714000
            ],
            [
                34.64,
                1707800400
            ],
            [
                35.06,
                1707886800
            ],
            [
                35.91,
                1707973200
            ],
            [
                36.1,
                1708059600
            ],
            [
                36,
                1708405200
            ],
            [
                38.36,
                1708491600
            ],
            [
                39.72,
                1708578000
            ],
            [
                40.56,
                1708664400
            ],
            [
                39.67,
                1708923600
            ],
            [
                39.84,
                1709010000
            ],
            [
                39.69,
                1709096400
            ],
            [
                39.81,
                1709182800
            ],
            [
                41.11,
                1709269200
            ],
            [
                40.93,
                1709528400
            ],
            [
                41.41,
                1709614800
            ],
            [
                41.69,
                1709701200
            ],
            [
                41.71,
                1709787600
            ],
            [
                41.73,
                1709874000
            ],
            [
                41.2,
                1710129600
            ],
            [
                41.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6286,
        "drug_name": "BAVENCIO (avelumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Bladder cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-30",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-bavencio-as-first-line-maintenance-treatment-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-301086396.html",
        "note": "FDA approval announced June 30, 2020.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3989,
        "drug_name": "DOJOLVI (triheptanoin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-06-30",
        "link": "https:\/\/www.benzinga.com\/pressreleases\/20\/06\/g16455801\/ultragenyx-announces-u-s-fda-approval-of-dojolvi-ux007triheptanoin-the-first-fda-approved-therapy-",
        "note": "FDA Approval announced June 30, 2020.",
        "company_entity_id": 258,
        "company_ticker": "RARE",
        "company_name": "Ultragenyx Pharmaceutical Inc.",
        "company_price": "47.6600",
        "company_change": -0.85,
        "company_percent_change": -1.75,
        "company_optionable": 1,
        "company_number_of_shares": 82335687,
        "price_change_sparkline": [
            [
                44.11,
                1706677200
            ],
            [
                44.1,
                1706763600
            ],
            [
                43.02,
                1706850000
            ],
            [
                44.76,
                1707109200
            ],
            [
                45.89,
                1707195600
            ],
            [
                44.71,
                1707282000
            ],
            [
                45.45,
                1707368400
            ],
            [
                46.73,
                1707454800
            ],
            [
                46.74,
                1707714000
            ],
            [
                43.98,
                1707800400
            ],
            [
                45.66,
                1707886800
            ],
            [
                46.26,
                1707973200
            ],
            [
                48.92,
                1708059600
            ],
            [
                47.87,
                1708405200
            ],
            [
                48.18,
                1708491600
            ],
            [
                48.88,
                1708578000
            ],
            [
                49.48,
                1708664400
            ],
            [
                50.25,
                1708923600
            ],
            [
                53.66,
                1709010000
            ],
            [
                52.75,
                1709096400
            ],
            [
                51.72,
                1709182800
            ],
            [
                53.69,
                1709269200
            ],
            [
                53.31,
                1709528400
            ],
            [
                51.47,
                1709614800
            ],
            [
                51.26,
                1709701200
            ],
            [
                50.85,
                1709787600
            ],
            [
                50.53,
                1709874000
            ],
            [
                48.51,
                1710129600
            ],
            [
                47.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6258,
        "drug_name": "RUKOBIA (Fostemsavir)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-02",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available\/",
        "note": "FDA Approval announced July 2, 2020.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6258,
        "drug_name": "RUKOBIA (Fostemsavir)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-02",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available\/",
        "note": "FDA Approval announced July 2, 2020.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4412,
        "drug_name": "QWO (collagenase clostridium histolyticum-aaes)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Edematous fibrosclerotic panniculopathy (\u201ccellulite\u201d)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-06",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-qwo-collagenase-clostridium-histolyticum-aaes-the-first-injectable-treatment-for-cellulite-301088803.html",
        "note": "FDA Approval announced July 6, 2020.",
        "company_entity_id": 130,
        "company_ticker": "ENDP",
        "company_name": "FTSE EPRA Europe Ex UK Dividend +",
        "company_price": "0.2926",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 235219612,
        "price_change_sparkline": [
            [
                0.0006,
                1706677200
            ],
            [
                0.0006,
                1706763600
            ],
            [
                0.0006,
                1706850000
            ],
            [
                0.0007,
                1707109200
            ],
            [
                0.0007,
                1707195600
            ],
            [
                0.0007,
                1707282000
            ],
            [
                0.0006,
                1707368400
            ],
            [
                0.0013,
                1707454800
            ],
            [
                0.0009,
                1707714000
            ],
            [
                0.001,
                1707800400
            ],
            [
                0.0007,
                1707886800
            ],
            [
                0.0009,
                1707973200
            ],
            [
                0.0006,
                1708059600
            ],
            [
                0.0006,
                1708405200
            ],
            [
                0.0006,
                1708491600
            ],
            [
                0.001,
                1708578000
            ],
            [
                0.0008,
                1708664400
            ],
            [
                0.0019,
                1708923600
            ],
            [
                0.001,
                1709010000
            ],
            [
                0.0014,
                1709096400
            ],
            [
                0.001,
                1709182800
            ],
            [
                0.005,
                1709269200
            ],
            [
                0.0012,
                1709528400
            ],
            [
                0.0012,
                1709614800
            ],
            [
                0.0012,
                1709701200
            ],
            [
                0.0012,
                1709787600
            ],
            [
                0.0011,
                1709874000
            ],
            [
                0.0011,
                1710129600
            ]
        ],
        "statuses": []
    },
    {
        "id": 6805,
        "drug_name": "Hulio (adalimumab-fkjp)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Humira biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-09",
        "link": "https:\/\/investor.mylan.com\/news-releases\/news-release-details\/mylan-and-fujifilm-kyowa-kirin-biologics-announce-us-fda",
        "note": "FDA Approval announced July 9, 2020.",
        "company_entity_id": 851,
        "company_ticker": "VTRS",
        "company_name": "Viatris Inc.",
        "company_price": "12.0600",
        "company_change": 0.09,
        "company_percent_change": 0.75,
        "company_optionable": 1,
        "company_number_of_shares": 1187569149,
        "price_change_sparkline": [
            [
                11.6559127625202,
                1706677200
            ],
            [
                11.754943457189,
                1706763600
            ],
            [
                11.7351373182553,
                1706850000
            ],
            [
                11.4677544426494,
                1707109200
            ],
            [
                11.7747495961228,
                1707195600
            ],
            [
                11.6262035541195,
                1707282000
            ],
            [
                11.4479483037157,
                1707368400
            ],
            [
                11.5667851373183,
                1707454800
            ],
            [
                11.8341680129241,
                1707714000
            ],
            [
                11.8539741518578,
                1707800400
            ],
            [
                11.9530048465267,
                1707886800
            ],
            [
                12.6957350565428,
                1707973200
            ],
            [
                12.933408723748,
                1708059600
            ],
            [
                13.1116639741519,
                1708405200
            ],
            [
                13.1314701130856,
                1708491600
            ],
            [
                13.2305008077544,
                1708578000
            ],
            [
                13.3988529886914,
                1708664400
            ],
            [
                13.2998222940226,
                1708923600
            ],
            [
                13.101760904685,
                1709010000
            ],
            [
                12.1708723747981,
                1709096400
            ],
            [
                12.2500969305331,
                1709182800
            ],
            [
                12.4679644588045,
                1709269200
            ],
            [
                12.2401938610662,
                1709528400
            ],
            [
                12.1609693053312,
                1709614800
            ],
            [
                12.0817447495961,
                1709701200
            ],
            [
                12.2104846526656,
                1709787600
            ],
            [
                12.26,
                1709874000
            ],
            [
                11.97,
                1710129600
            ],
            [
                12.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5555,
        "drug_name": "Leronlimab (PRO 140)",
        "clinical_trial_id": "NCT03902522",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "BLA Filing",
        "value": "blaFiling",
        "simplified_stage": "phase4",
        "stageid": 12,
        "stage_name": "BLA Filing",
        "date": "2020-07-13",
        "link": "https:\/\/www.cytodyn.com\/investors\/news-events\/press-releases\/detail\/449\/update-on-hiv-bla-pdufa-fda-requested-more-information-to",
        "note": "Refusal to file letter announced July 13, 2020.",
        "company_entity_id": 639,
        "company_ticker": "CYDY",
        "company_name": "Cytodyn Inc",
        "company_price": "0.1750",
        "company_change": -0.010000000000000009,
        "company_percent_change": -5.3,
        "company_optionable": 0,
        "company_number_of_shares": 979527000,
        "price_change_sparkline": [
            [
                0.1719,
                1706677200
            ],
            [
                0.179,
                1706763600
            ],
            [
                0.1684,
                1706850000
            ],
            [
                0.16192,
                1707109200
            ],
            [
                0.162,
                1707195600
            ],
            [
                0.1571,
                1707282000
            ],
            [
                0.1616,
                1707368400
            ],
            [
                0.1651,
                1707454800
            ],
            [
                0.168971,
                1707714000
            ],
            [
                0.17,
                1707800400
            ],
            [
                0.17125,
                1707886800
            ],
            [
                0.16904,
                1707973200
            ],
            [
                0.16695,
                1708059600
            ],
            [
                0.16546,
                1708405200
            ],
            [
                0.1649,
                1708491600
            ],
            [
                0.1661,
                1708578000
            ],
            [
                0.1651,
                1708664400
            ],
            [
                0.167119,
                1708923600
            ],
            [
                0.159,
                1709010000
            ],
            [
                0.1603,
                1709096400
            ],
            [
                0.2575,
                1709182800
            ],
            [
                0.2025,
                1709269200
            ],
            [
                0.25,
                1709528400
            ],
            [
                0.2001,
                1709614800
            ],
            [
                0.196,
                1709701200
            ],
            [
                0.181,
                1709787600
            ],
            [
                0.18804,
                1709874000
            ],
            [
                0.18,
                1710129600
            ],
            [
                0.175,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6076,
        "drug_name": "TREMFYA (Guselkumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": " Psoriatic Arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-14",
        "link": "https:\/\/www.janssen.com\/tremfya-guselkumab-approved-us-food-and-drug-administration-first-selective-interleukin-il-23",
        "note": "FDA Approval announced July 14, 2020.",
        "company_entity_id": 538,
        "company_ticker": "MOR",
        "company_name": "MorphoSys AG",
        "company_price": "18.1700",
        "company_change": 0.28,
        "company_percent_change": 1.5699999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 136927772,
        "price_change_sparkline": [
            [
                10.51,
                1706677200
            ],
            [
                11.505,
                1706763600
            ],
            [
                11.07,
                1706850000
            ],
            [
                17.27,
                1707109200
            ],
            [
                16.27,
                1707195600
            ],
            [
                17,
                1707282000
            ],
            [
                17.15,
                1707368400
            ],
            [
                17.15,
                1707454800
            ],
            [
                17.33,
                1707714000
            ],
            [
                17.18,
                1707800400
            ],
            [
                17.43,
                1707886800
            ],
            [
                17.49,
                1707973200
            ],
            [
                17.48,
                1708059600
            ],
            [
                17.59,
                1708405200
            ],
            [
                17.65,
                1708491600
            ],
            [
                17.71,
                1708578000
            ],
            [
                17.62,
                1708664400
            ],
            [
                17.69,
                1708923600
            ],
            [
                17.67,
                1709010000
            ],
            [
                17.58,
                1709096400
            ],
            [
                17.6,
                1709182800
            ],
            [
                17.7,
                1709269200
            ],
            [
                17.74,
                1709528400
            ],
            [
                17.69,
                1709614800
            ],
            [
                17.8,
                1709701200
            ],
            [
                17.85,
                1709787600
            ],
            [
                17.91,
                1709874000
            ],
            [
                17.89,
                1710129600
            ],
            [
                18.17,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6076,
        "drug_name": "TREMFYA (Guselkumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": " Psoriatic Arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-14",
        "link": "https:\/\/www.janssen.com\/tremfya-guselkumab-approved-us-food-and-drug-administration-first-selective-interleukin-il-23",
        "note": "FDA Approval announced July 14, 2020.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2641,
        "drug_name": "XYWAV",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cataplexy and Excessive Daytime Sleepiness in Narcolepsy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-22",
        "link": "http:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-approval-xywavtm-calcium",
        "note": "FDA Approval announced July 22, 2020.",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3321,
        "drug_name": "TECARTUS (brexucabtagene autoleucel) - (ZUMA-2)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or Refractory Mantle Cell Lymphoma (r\/r MCL) - cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-24",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200724005428\/en\/",
        "note": "FDA approval announced July 24, 2020.",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2969,
        "drug_name": "BREZTRI AEROSPHERE (budesonide\/glycopyrrolate\/formoterol fumarate)",
        "clinical_trial_id": "NCT02465567",
        "has_trial_insight_page": 0,
        "indication": "Chronic obstructive pulmonary disease (COPD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-24",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200724005241\/en\/",
        "note": "FDA approval announced July 24, 2020.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4713,
        "drug_name": "CABOMETYX (Cabozantinib) + TECENTRIQ (atezolizumab) and Zelboraf (vemurafenib) - (IMspire150)",
        "clinical_trial_id": "NCT02908672",
        "has_trial_insight_page": 0,
        "indication": "BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-30",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200730006043\/en\/",
        "note": "FDA approval announced July 30, 2020.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4713,
        "drug_name": "CABOMETYX (Cabozantinib) + TECENTRIQ (atezolizumab) and Zelboraf (vemurafenib) - (IMspire150)",
        "clinical_trial_id": "NCT02908672",
        "has_trial_insight_page": 0,
        "indication": "BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-30",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200730006043\/en\/",
        "note": "FDA approval announced July 30, 2020.",
        "company_entity_id": 137,
        "company_ticker": "EXEL",
        "company_name": "Exelixis Inc.",
        "company_price": "22.6900",
        "company_change": 0.23,
        "company_percent_change": 1.02,
        "company_optionable": 1,
        "company_number_of_shares": 303194259,
        "price_change_sparkline": [
            [
                21.76,
                1706677200
            ],
            [
                21.75,
                1706763600
            ],
            [
                21.49,
                1706850000
            ],
            [
                21.4,
                1707109200
            ],
            [
                21.83,
                1707195600
            ],
            [
                20.18,
                1707282000
            ],
            [
                20.17,
                1707368400
            ],
            [
                20.22,
                1707454800
            ],
            [
                20.39,
                1707714000
            ],
            [
                20.23,
                1707800400
            ],
            [
                20.39,
                1707886800
            ],
            [
                20.59,
                1707973200
            ],
            [
                20.48,
                1708059600
            ],
            [
                20.63,
                1708405200
            ],
            [
                20.72,
                1708491600
            ],
            [
                20.71,
                1708578000
            ],
            [
                21.53,
                1708664400
            ],
            [
                21.96,
                1708923600
            ],
            [
                21.71,
                1709010000
            ],
            [
                21.91,
                1709096400
            ],
            [
                21.9,
                1709182800
            ],
            [
                22.24,
                1709269200
            ],
            [
                22.55,
                1709528400
            ],
            [
                22.26,
                1709614800
            ],
            [
                22.38,
                1709701200
            ],
            [
                22.09,
                1709787600
            ],
            [
                22.21,
                1709874000
            ],
            [
                22.46,
                1710129600
            ],
            [
                22.69,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4697,
        "drug_name": "MONJUVI (tafasitamab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or refractory diffuse large B cell lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-31",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200731005497\/en\/",
        "note": "FDA Approval announced July 31, 2020.",
        "company_entity_id": 538,
        "company_ticker": "MOR",
        "company_name": "MorphoSys AG",
        "company_price": "18.1700",
        "company_change": 0.28,
        "company_percent_change": 1.5699999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 136927772,
        "price_change_sparkline": [
            [
                10.51,
                1706677200
            ],
            [
                11.505,
                1706763600
            ],
            [
                11.07,
                1706850000
            ],
            [
                17.27,
                1707109200
            ],
            [
                16.27,
                1707195600
            ],
            [
                17,
                1707282000
            ],
            [
                17.15,
                1707368400
            ],
            [
                17.15,
                1707454800
            ],
            [
                17.33,
                1707714000
            ],
            [
                17.18,
                1707800400
            ],
            [
                17.43,
                1707886800
            ],
            [
                17.49,
                1707973200
            ],
            [
                17.48,
                1708059600
            ],
            [
                17.59,
                1708405200
            ],
            [
                17.65,
                1708491600
            ],
            [
                17.71,
                1708578000
            ],
            [
                17.62,
                1708664400
            ],
            [
                17.69,
                1708923600
            ],
            [
                17.67,
                1709010000
            ],
            [
                17.58,
                1709096400
            ],
            [
                17.6,
                1709182800
            ],
            [
                17.7,
                1709269200
            ],
            [
                17.74,
                1709528400
            ],
            [
                17.69,
                1709614800
            ],
            [
                17.8,
                1709701200
            ],
            [
                17.85,
                1709787600
            ],
            [
                17.91,
                1709874000
            ],
            [
                17.89,
                1710129600
            ],
            [
                18.17,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4697,
        "drug_name": "MONJUVI (tafasitamab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or refractory diffuse large B cell lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-31",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200731005497\/en\/",
        "note": "FDA Approval announced July 31, 2020.",
        "company_entity_id": 316,
        "company_ticker": "XNCR",
        "company_name": "Xencor Inc.",
        "company_price": "22.8000",
        "company_change": -0.32999999999999996,
        "company_percent_change": -1.4300000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 61120272,
        "price_change_sparkline": [
            [
                18.7,
                1706677200
            ],
            [
                19.06,
                1706763600
            ],
            [
                18.74,
                1706850000
            ],
            [
                18.79,
                1707109200
            ],
            [
                19.11,
                1707195600
            ],
            [
                18.7,
                1707282000
            ],
            [
                18.65,
                1707368400
            ],
            [
                19.42,
                1707454800
            ],
            [
                20.51,
                1707714000
            ],
            [
                19.12,
                1707800400
            ],
            [
                20.1,
                1707886800
            ],
            [
                21.3,
                1707973200
            ],
            [
                24.15,
                1708059600
            ],
            [
                23.5,
                1708405200
            ],
            [
                24.09,
                1708491600
            ],
            [
                24.39,
                1708578000
            ],
            [
                24.47,
                1708664400
            ],
            [
                25.87,
                1708923600
            ],
            [
                26.52,
                1709010000
            ],
            [
                22.79,
                1709096400
            ],
            [
                22.95,
                1709182800
            ],
            [
                23.82,
                1709269200
            ],
            [
                23.92,
                1709528400
            ],
            [
                22.85,
                1709614800
            ],
            [
                23.83,
                1709701200
            ],
            [
                23.79,
                1709787600
            ],
            [
                24.25,
                1709874000
            ],
            [
                23.13,
                1710129600
            ],
            [
                22.8,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4697,
        "drug_name": "MONJUVI (tafasitamab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed or refractory diffuse large B cell lymphoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-07-31",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200731005497\/en\/",
        "note": "FDA Approval announced July 31, 2020.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4032,
        "drug_name": "EPIDIOLEX (cannabidiol)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Tuberous Sclerosis Complex",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-03",
        "link": "https:\/\/ir.gwpharm.com\/news-releases\/news-release-details\/fda-approves-epidiolexr-cannabidiol-oral-solution-treat-seizures",
        "note": "FDA approval announced August 3, 2020.",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6103,
        "drug_name": "SPRAVATO (esketamine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Major depressive disorder (MDD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-03",
        "link": "http:\/\/johnsonandjohnson.gcs-web.com\/static-files\/b287082d-780a-4cd5-a4a3-12b1b152600f",
        "note": "FDA approval announced August 3, 2020.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5202,
        "drug_name": "BLENREP (belantamab mafodotin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-05",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200805006105\/en\/FDA-Approves-GSK%E2%80%99s-BLENREP-belantamab-mafodotin-blmf-Treatment",
        "note": "FDA approval granted August 5, 2020.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5202,
        "drug_name": "BLENREP (belantamab mafodotin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-08-05",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200805006105\/en\/FDA-Approves-GSK%E2%80%99s-BLENREP-belantamab-mafodotin-blmf-Treatment",
        "note": "FDA approval granted August 5, 2020.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    }
]